MWNA
CBAY

Marshall Wace North America’s Cymabay Therapeutics CBAY Stock Holding History

Marshall Wace North America’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-365,866
Closed -$541K – 1558
2020
Q1 		$541K Buy
+365,866
New +$614K ﹤0.01% 740
2019
Q4 		– Sell
-8,726
Closed -$45K – 1680
2019
Q3 		$45K Sell
8,726
-14,152
-62% -$85.7K ﹤0.01% 1172
2019
Q2 		$164K Sell
22,878
-99,914
-81% -$1.13M ﹤0.01% 1053
2019
Q1 		$1.63M Buy
122,792
+116,135
+1,745% +$1.24M 0.01% 559
2018
Q4 		$52K Buy
+6,657
New +$63.4K ﹤0.01% 1243
2017
Q3 		– Sell
-40,416
Closed -$242K – 1560
2017
Q2 		$242K Buy
+40,416
New +$172K ﹤0.01% 1194

Other funds holding CBAY

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $694M AUM 79.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return